PALA, Daniele
 Distribuzione geografica
Continente #
NA - Nord America 2.143
AS - Asia 1.952
EU - Europa 1.442
SA - Sud America 226
AF - Africa 116
OC - Oceania 1
Totale 5.880
Nazione #
US - Stati Uniti d'America 2.085
SG - Singapore 642
CN - Cina 581
FI - Finlandia 319
VN - Vietnam 311
IT - Italia 259
IE - Irlanda 245
SE - Svezia 209
BR - Brasile 177
DE - Germania 136
HK - Hong Kong 132
TR - Turchia 82
FR - Francia 77
ZA - Sudafrica 74
BD - Bangladesh 49
NL - Olanda 48
GB - Regno Unito 39
IN - India 35
CA - Canada 27
AR - Argentina 24
BE - Belgio 23
CI - Costa d'Avorio 22
MX - Messico 21
UA - Ucraina 21
JP - Giappone 17
IQ - Iraq 14
RU - Federazione Russa 13
PH - Filippine 12
ES - Italia 10
ID - Indonesia 10
JO - Giordania 9
MA - Marocco 8
PK - Pakistan 8
TH - Thailandia 8
CZ - Repubblica Ceca 7
LT - Lituania 7
VE - Venezuela 7
EC - Ecuador 5
HU - Ungheria 5
PL - Polonia 5
CL - Cile 4
PS - Palestinian Territory 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AT - Austria 3
AZ - Azerbaigian 3
BO - Bolivia 3
CO - Colombia 3
HN - Honduras 3
IL - Israele 3
KE - Kenya 3
KR - Corea 3
NP - Nepal 3
PY - Paraguay 3
TN - Tunisia 3
TW - Taiwan 3
AO - Angola 2
KG - Kirghizistan 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
UZ - Uzbekistan 2
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TV - Tuvalu 1
VG - Isole Vergini Britanniche 1
Totale 5.880
Città #
Singapore 342
Ashburn 250
Dublin 245
Chandler 238
San Jose 211
Santa Clara 155
Dallas 144
Beijing 142
Parma 131
Hong Kong 121
Ho Chi Minh City 97
Dearborn 82
Hanoi 75
Izmir 71
Johannesburg 71
Boardman 69
Ann Arbor 66
Nanjing 63
Los Angeles 54
New York 52
Shanghai 50
Bremen 42
Princeton 42
Jacksonville 38
Lauterbourg 38
Munich 37
Wilmington 35
Helsinki 25
Abidjan 22
Brussels 21
Columbus 21
San Mateo 20
Kunming 19
Shenyang 19
São Paulo 16
Düsseldorf 15
Hebei 15
Hefei 15
Tokyo 15
Nanchang 14
Seattle 13
Toronto 13
Turku 13
Jinan 12
Buffalo 11
Guangzhou 11
Haiphong 11
Jiaxing 11
Moscow 11
Changsha 10
Da Nang 10
London 10
Orem 10
Chennai 9
Hangzhou 9
Milan 9
Phoenix 9
Amman 8
Atlanta 8
Council Bluffs 8
Mexico City 8
Modena 8
Montreal 8
Rio de Janeiro 8
Tianjin 8
Belo Horizonte 7
Boston 7
Brooklyn 7
Denver 7
Jakarta 7
Norwalk 7
Pune 7
Rome 7
Stockholm 7
The Dalles 7
Woodbridge 7
Can Tho 6
Ninh Bình 6
Poplar 6
San Francisco 6
Bangkok 5
Fremont 5
Grafing 5
Houston 5
Porto Alegre 5
Zhengzhou 5
Ankara 4
Baghdad 4
Borås 4
Brescia 4
Fuzhou 4
Haikou 4
Hyderabad 4
Lahore 4
New Delhi 4
Nova Iguaçu 4
Nuremberg 4
Olomouc 4
Shijiazhuang 4
Springfield 4
Totale 3.631
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 243
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 219
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 217
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 208
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 202
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 185
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 176
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 168
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 163
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 161
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 156
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 150
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 149
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 148
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 148
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 147
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 145
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 143
Target-hopping: a useful approach to identify novel Eph receptor antagonists 139
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 137
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 137
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 136
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 133
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 133
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 132
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 129
New classes of potent heparanase inhibitors from ligand-based virtual screening 127
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 126
Homology models of melatonin receptors: challenges and recent advances. 118
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 105
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors. 96
Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. 94
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 89
Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties 86
Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. 85
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate 81
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase 79
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) 76
MT1-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-[[(3-O-Substituted)anilino]alkyl]amides. 75
Application of comparative modelling to the design and discovery of novel GPCR ligands 1
Totale 5.975
Categoria #
all - tutte 19.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.778


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 0 0 0 8
2021/2022184 6 2 3 28 2 7 8 25 7 14 16 66
2022/2023891 99 107 39 60 103 97 14 48 299 2 21 2
2023/2024288 16 27 4 13 21 61 36 24 8 14 24 40
2024/2025994 26 64 61 55 120 109 49 45 132 76 97 160
2025/20262.312 212 269 235 188 291 132 260 74 332 167 94 58
Totale 5.975